

Evoform Biosciences to Report Second Quarter 2020 Results and Provide Corporate Update on Tuesday, August 4, 2020

-- Conference Call Scheduled for 11:00 a.m. EDT --

SAN DIEGO, July 23, 2020 /PRNewswire/ -- Evoform Biosciences, Inc. (NASDAQ: EVFM) will hold a webcast and conference call to discuss the Company's financial results and business highlights for the second quarter ended June 30, 2020.

Date	Tuesday, August 4, 2020
Time	11:00 a.m. EDT (8:00 a.m. PDT)
Dial-in numbers	(866) 503-5561 (U.S. toll-free) or (253) 336-2965
Conference ID	5884198
Webcast (live and archived)	www.evoform.com under " Investors " or click here

The live webcast and related slide presentation can be accessed on the Company's Investor page at <https://evoform.investorroom.com/events>. Please connect to the Company's website at least 15 minutes prior to the start of the call to download any software that may be required. If participating by phone, please dial in approximately 10 minutes prior to the start of the call.

A telephone replay will be available approximately two hours after the call through Friday, August 7, 2020 at (855) 859-2056 (U.S.) or (404) 537-3406 (International), conference ID 5884198. The webcast will be archived at <https://evoform.investorroom.com/events>.

About Evoform Biosciences, Inc.

Evoform Biosciences, Inc., (NASDAQ: EVFM) is a commercial-stage biopharmaceutical company committed to developing and commercializing innovative products to address unmet needs in women's sexual and reproductive health, including hormone-free, woman-controlled contraception and protection from certain sexually transmitted infections (STIs). The Company's first commercial product, Phexxi™ (lactic acid, citric acid and potassium bitartrate), is the first and only vaginal pH regulator approved in the United States for the prevention of pregnancy. The Company is also advancing EVO100 into Phase 3 clinical trials for the prevention of urogenital transmission of both *Chlamydia trachomatis* infection (chlamydia) and *Neisseria gonorrhoeae* infection (gonorrhea) in women.

Contact

Investor Relations

Amy Raskopf

Evoform Biosciences

araskopf@evoform.com

O: (858) 550-1900 x167

M: (917) 673-5775

Media

Cara Miller
Evoform Biosciences
cmiller@evoform.com
O: (858) 550-1900 x272

SOURCE Evoform Biosciences, Inc.
